Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine in vitro and in vivo

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4707-4712

  Murphey Corb, Michael ^a   Rajakumar, Premeela ^b   Michael, Heather ^a   Nyaundi, Julia ^a   Didier, Peter J ^c   Reeve, Aaron B ^a   Mitsuya, Hiroaki ^e   Sarafianos, Stefan G ^d   Parniak, Michael A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d University of Missouri   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' ETHYLNYL 2 FLUORO 2' DEOXYADENOSINE; EMTRICITABINE; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIARRHEA; GENOTYPE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION; WEIGHT REDUCTION;

ADENINE; ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; DEOXYADENOSINES; DEOXYCYTIDINE; LEUKOCYTES, MONONUCLEAR; MACACA MULATTA; MALE; MUTATION; ORGANOPHOSPHONATES; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD; ZIDOVUDINE;

EID: 84865412652     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00723-12     Document Type: Article

References (25)

1. Amedee AM, et al. 1995. Genotypic selection of simian immunodeficiency virus in macaque infants infected transplacentally. J. Virol. 69:7982-7990.
2. Amedee AM, et al. 1996. Genotypic analysis of infant macaques infected transplacentally and orally. J. Med. Primatol. 25:225-235. (Pubitemid 126463684)
3. Annamalai L, et al. 2010. Myocarditis in CD8-depleted SIV-infected rhesus macaques after short-term dual therapy with nucleoside and nucleotide reverse transcriptase inhibitors. PLoS One 5:e14429.
4. Fuller DH, et al. 2002. Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J. Virol. 76:3309-3317. (Pubitemid 34224533)
5. Fuller DH, et al. 2006. DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued. Virology 348:200-215.
6. Fuller DH, et al. 2012. Therapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaques. PLoS One 7:e33715.
7. Gagliani LH, et al. 2011. The association between primary antiretroviral resistance and HAART virologic failure in a developing set. AIDS Res. Hum. Retrovir. 27:251-256.
8. Graf T, et al. 2011. HIV-1 genetic diversity and drug resistance among treatment naive patients from southern Brazil: an association of HIV-1 subtypes with exposure categories. J. Clin. Virol. 51:186-191.
9. Hattori S, et al. 2009. Potent activity of a nucleoside reverse transcriptase inhibitor, 4′-ethynyl-2-fluoro-2′-deoxyadenosine, against HIV-1 infection in Hu-PBMC-NOD/SCID/JAK3null (NOJ) mouse model. Antimicrob. Agents Chemother. 53:3887-3893.
10. Ibe S, Sugiura W. 2011. Clinical significance of HIV reverse- transcriptase inhibitor-resistance mutations. Future Microbiol. 6:295-315.
11. Ilina T, Parniak MA. 2008. HIV-1 reverse transcriptase inhibitors, p 121-167. In Jeang KT, et al (ed), HIV-1: molecular biogenesis and pathogenesis: clinical applications, 2nd ed. Advances in pharmacology. Academic Press, New York, NY.
12. Karim QA, et al. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168-1174.
13. Kawamoto A, et al. 2008. 2′-Deoxy-4′-C-ethynyl-2-halo- adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Int. J. Biochem. Cell Biol. 40:2410-2420.
14. Kohgo S, et al. 2003. Synthesis of 4′-C-ethynyl and 4′-C cyano purine nucleosides from natural nucleosides and their anti-HIV activity. Nucleosides Nucleotides Nucleic Acids 22:887-889. (Pubitemid 37139282)
15. Michailidis E, et al. 2009. Mechanism of inhibition of HIV-1 reverse transcriptase by 4′-ethynyl-2-fluoro-2′-deoxyadenosine triphosphate, a translocation defective reverse transcriptase inhibitor. J. Biol. Chem. 284:35681-35691.
16. Nakata H, et al. 2007. Antiviral activity against HIV-1, intracellular metabolism, and effects on human DNA polymerases of 4′-ethynyl-2-fluoro- 2′-deoxyadenosine. Antimicrob. Agents Chemother. 51:2701-2708. (Pubitemid 47206202)
17. Ohrui H, et al. 2007. 2′-Deoxy-4′-C-ethynyl-2- fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against wide spectrum of HIV-1 strains, favorable toxic profiles, and stability in plasma. Nucleosides Nucleotides Nucleic Acids 26:1543-1546. (Pubitemid 350240765)
18. Puthanakit T, et al. 2010. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. HIV Med. 11:565-572.
19. Seman AL, Pewen WF, Fresh LF, Martin LN, Murphey-Corb M. 2000. The replicative capacity of rhesus macaque peripheral blood mononuclear cells for simian immunodeficiency virus in vitro is predictive of the rate of progression to AIDS in vivo. J. Gen. Virol. 81:2441-2449.
20. Sukasem C, et al. 2007. Surveillance of genotypic resistance mutations in chronic HIV-1 treated individuals after completion of the national access to antiretroviral program in Thailand. Infection 35:81-88. (Pubitemid 46536780)
21. Taber R, et al. 2006. Effects of monotherapy with (R)-9-(2- phosphonylmethoxypropyl) adenine (PMPA) on the evolution of a primary simian immunodeficiency virus (SIV) isolate. Virology 354:116-131. (Pubitemid 44468116)
22. Trichel AM, et al. 1997. SIV/DeltaB670 transmission across oral, colonic, and vaginal mucosae in the macaque. J. Med. Primatol. 26:3-10. (Pubitemid 127515859)
23. Van Rompay KK, et al. 2002. Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J. Virol. 76:6083-6092. (Pubitemid 34556303)
24. Van Rompay KK, et al. 2007. Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology 4:25.
25. Westin MR, et al. 2011. Resistance-associated mutation prevalence according to subtypes B and non-B of HIV type 1 in antiretroviral-experienced patients in Minas Gerais, Brazil. AIDS Res. Hum. Retrovir. 27:981-987.